Response evaluation after stereotactic ablative radiotherapy for localized non-small-cell lung cancer - an equipoise of available resource and accuracy.

Abstract

There is growing evidence supporting the use of stereotactic ablative radiotherapy (SABR) on the treatment of localized stage non-small-cell Lung cancer (NSCLC). Distinctive imaging challenges are posed post-SABR treatment. Thus, it is imperative to provide guidance on assessing treatment response, especially for new adopters. This commentary is about filling a gap in response evaluation after SABR for localized NSCLC.